BioLineRx, Yissum and Hadasit, Regentech, Johns Hopkins University, White House, NIH, Rules-Based Medicine, University of New Mexico, NCI | GenomeWeb
BioLineRx Licenses Anti-Cancer Compound From Israeli Universities
 
BioLineRx last week said that it has gained an exclusive worldwide license to the small molecule BL-4060 from Yissum, the technology-transfer arm of the Hebrew University of Jerusalem, and Hadasit, the tech-transfer company of Hadassah medical organization.
 
BL-4060 is an analog of the fatty molecule ceramide for the treatment of cancer. Ceramide is a strong pro-apoptotic agent that induces apoptosis in a variety of cancer cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.